Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPARδ-AMPK-PGC-1α Pathway in Dyslipidemic Conditions

This study is aimed at elucidating how aspirin could systemically and simultaneously normalize nonalcoholic fatty liver disease (NAFLD) and atherosclerosis through both in vitro and in vivo studies in hyperlipidemic conditions. We evaluated the effects and mechanism of aspirin on the levels of vario...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Yoon-Mi, Lee, Yong-Jik, Jang, Yoo-Na, Kim, Hyun-Min, Seo, Hong Seog, Jung, Tae Woo, Jeong, Ji Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106881/
https://www.ncbi.nlm.nih.gov/pubmed/32258142
http://dx.doi.org/10.1155/2020/7806860

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106881/
https://www.ncbi.nlm.nih.gov/pubmed/32258142
http://dx.doi.org/10.1155/2020/7806860

Ejemplares similares